- Home
- JACS vs ORIC Comparison
JACS vs ORIC Comparison
Compare JACS & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JACS
- ORIC
- Stock Information
- Founded
- JACS 2024
- ORIC 2014
- Country
- JACS United States
- ORIC United States
- Employees
- JACS N/A
- ORIC N/A
- Industry
- JACS
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- JACS
- ORIC Health Care
- Exchange
- JACS NYSE
- ORIC Nasdaq
- Market Cap
- JACS 303.6M
- ORIC 362.9M
- IPO Year
- JACS 2024
- ORIC 2020
- Fundamental
- Price
- JACS $10.33
- ORIC $10.85
- Analyst Decision
- JACS
- ORIC Strong Buy
- Analyst Count
- JACS 0
- ORIC 9
- Target Price
- JACS N/A
- ORIC $18.29
- AVG Volume (30 Days)
- JACS 67.6K
- ORIC 932.0K
- Earning Date
- JACS 01-01-0001
- ORIC 08-11-2025
- Dividend Yield
- JACS N/A
- ORIC N/A
- EPS Growth
- JACS N/A
- ORIC N/A
- EPS
- JACS N/A
- ORIC N/A
- Revenue
- JACS N/A
- ORIC N/A
- Revenue This Year
- JACS N/A
- ORIC N/A
- Revenue Next Year
- JACS N/A
- ORIC N/A
- P/E Ratio
- JACS $267.38
- ORIC N/A
- Revenue Growth
- JACS N/A
- ORIC N/A
- 52 Week Low
- JACS $9.94
- ORIC $3.90
- 52 Week High
- JACS $10.41
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- JACS N/A
- ORIC 61.82
- Support Level
- JACS N/A
- ORIC $10.72
- Resistance Level
- JACS N/A
- ORIC $11.45
- Average True Range (ATR)
- JACS 0.00
- ORIC 0.58
- MACD
- JACS 0.00
- ORIC -0.08
- Stochastic Oscillator
- JACS 0.00
- ORIC 57.65
About JACS JACKSON ACQUISITION COMPANY II
Jackson Acquisition Co II is a newly incorporated blank check company.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.